Effectiveness of Resistance Exercises Added to Aerobic and Balance Exercises in Parkinson's Disease
The Effects of Resistive Exercises Added to Aerobic and Balance Exercises on Quality of Life, Activities of Daily Living, Cognitive Functions, and Sarcopenia Parameters in Patients With Early-Stage Parkinson's Disease: A Prospective Randomized Controlled Study.
調査の概要
詳細な説明
Parkinson's disease (PD) is a neurodegenerative disease characterized by bradykinesia, rigidity, resting tremor and postural instability. It can lead to numerous motor, neuropsychiatric, cognitive, and autonomic symptoms. In advanced stages, it can increase the risk of falling by causing postural instability. Sarcopenia is characterized by a decrease in muscle mass and function. Sarcopenia prevalence increases with age, leading to increased fragility and risk of falling. Studies have shown that various exercise programs, including aerobic, balance, and resistive exercises, have positive effects on rigidity, tremor, gait disorders, and physical capacity in patients diagnosed with PD. The purpose of this study is to evaluate the effects of resistive exercises added to aerobic and balance exercises on quality of life, activities of daily living, cognitive functions, and sarcopenia parameters in patients diagnosed with early-stage PD.
Adults who aged between 40-70 years, diagnosed with PD and meet predefined inclusion and exclusion criteria will be enrolled and randomly assigned to one of two exercise based treatment groups. Both groups will receive aerobic and balance exercises, while one group will additionaly receive resistive exercises. Both groups will undergo exercise programs three days a week for eight weeks. Evaluations will be conducted using the The Parkinson's Disease Questionnaire-39 (PDQ-39), Short Physical Performance Battery (SPPB), SARC-F Questionnaire, Berg Balance Test, Katz Index of Independence in Activities of Daily Living, Montreal Cognitive Assesment (MoCA), Patient Health Questionnaire-9 (PH-9), functional performance tests, grip strentgh measurements and quadriceps muscle thickness measurement via ultrasonography. Evaluations will be performed at baseline, on the first day after the treatment and 4 weeks after the end of the treatment.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Istanbul、トルコ(Türkiye)
- Şişli Hamidiye Etfal Training and Research Hospital
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Adults aged 40 to 70 years
- Patients diagnosed with Modified Hoehn-Yahr stage 1-3 Parkinson's disease
- Patients diagnosed with Parkinson's disease for more than 1 year
- Patients who can mobilize without an assistive device
Exclusion Criteria:
- Patients diagnosed with Parkinson Plus syndrome
- History of uncontrolled hypertension
- History of uncontrolled diabetes mellitus
- History of serebrovascular disease within the past 6 months
- History of miyocardial infarction within the past 6 months
- History of knee or hip artroplasty surgery
- History of severe cardiac arrythmia
- Presence of cardiac pacemaker
- Presence of severe dementia
- History of severe psychiatric disorders
- Patients who have on dialysis
- Presence of acute infection
- Pregnancy
- History of malignancy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Aerobic and Balance Exercise Group
Participants will receive an exercise program with 3 days a week for 8 weeks.
Each treatment session will not exceed 45 minutes.
Program will include aerobic exercises with 15 minutes on a treadmill, aiming not to exceed 85% of maximum heart rate and balance exercises including tandem stance, tandem walk, side stepping, backward walking, single leg stance.
|
An 3 days a week for 8 weeks aerobic and balance exercises program
他の名前:
A 3 days a week for 8 weeks aerobic, balance and resistive exercises program
他の名前:
|
|
実験的:Aerobic, Balance and Resistive Exercise Group
Participants will receive an exercise program with 3 days a week for 8 weeks.
Each treatment session will not exceed 45 minutes.
Program will include aerobic exercises with 15 minutes on a treadmill, aiming not to exceed 85% of maximum heart rate; balance exercises including tandem stance, tandem walk, side stepping, backward walking, single leg stance and resistive exercises for upper and lower extremity
|
An 3 days a week for 8 weeks aerobic and balance exercises program
他の名前:
A 3 days a week for 8 weeks aerobic, balance and resistive exercises program
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Grip strenght
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Grip strength is measured using a hydraulic hand dynamometer with the dominant hand.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
Chair Stand Test
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Chair Stand Test is used to assess muscle function.
Patients asked to sit and stand on a chair for 5 times.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
Gait Speed
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Gait speed is assessed by measuring the time it takes the patient to walk a distance of 4 meters.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quadriceps Muscle Thickness Measurement
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Quadriceps muscle thickness measurement is performed ultrasonographically with a linear probe, without compression, with the patient in the supine position, from the anterior side, at the midpoint of the linear line passing between the anterior superior iliac spine (ASIS) and the upper pole of the patella.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
Time-Up And Go Test
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
It is measured by the time it takes for a person to get up from their chair, walk 3 meters, return, and sit back down.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
SARC-F Questionnaire
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
SARC-F is a screening tool to identify propable sarcopenic patients.
The total score ranges from 0 to 10; a score of 4 or higher indicates a risk of sarcopenia.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
The Short Physical Performance Battery (SPPB)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
The Short Physical Performance Battery (SPPB) is a assessment tool for evaluating physical performance.
The total score ranging from 0 to 12 where 0 indicates worst performance and 12 indicates best performance.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
Berg Balance Scale
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Berg Balance Scale is a 14-item test used to evaluate functional balance and fall risk in patiens.
Each item is scored on a 0-4 scale.
The total score is ranging 0 to 56 where lower scores indicates higher fall risk.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
The Parkinson's Disease Questionnaire-39 (PDQ-39)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
The Parkinson's Disease Questionnaire-39 (PDQ-39) is used to assess quality of life among with patients with Parkinson's disease.
The scale consists of 39 multiple-choice items covering 8 factors.
Each question is scored between 0 and 4. Higher scores indicate a deterioration in quality of life.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
The Patient Health Questionnaire (PHQ)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
The Patient Health Questionnaire-9 (PHQ-9) is diagnostic and screening tool for depression.
The PHQ-9 measures symptoms over the past 2 weeks on a scale of 0 (not at all) to 3 (nearly every day).
Total score ranges 0 to 27.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
Katz Index of Independence in Activities of Daily Living
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
Katz Index of Independence in Activities of Daily Living is used to assess basic functional status and the level of independency.
The total score ranging from 0 to 6, where 0 indicates severe functional impairment and 6 indicates full function.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
|
The Montreal Cognitive Assessment (MoCA)
時間枠:Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
The Montreal Cognitive Assessment (MoCA) is used to detect cognitive impairment.
The total score ranges 0 to 30 which scores of 26 to 30 are generally considered normal cognitive function.
|
Baseline (pre-treatment), Day 1 post-treatment, Week 4 post-treatment
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Vieira de Moraes Filho A, Chaves SN, Martins WR, Tolentino GP, de Cassia Pereira Pinto Homem R, Landim de Farias G, Fischer BL, Oliveira JA, Pereira SKA, Vidal SE, Mota MR, Moreno Lima R, Jaco de Oliveira R. Progressive Resistance Training Improves Bradykinesia, Motor Symptoms and Functional Performance in Patients with Parkinson's Disease. Clin Interv Aging. 2020 Jan 23;15:87-95. doi: 10.2147/CIA.S231359. eCollection 2020.
- Leal LC, Abrahin O, Rodrigues RP, da Silva MC, Araujo AP, de Sousa EC, Pimentel CP, Cortinhas-Alves EA. Low-volume resistance training improves the functional capacity of older individuals with Parkinson's disease. Geriatr Gerontol Int. 2019 Jul;19(7):635-640. doi: 10.1111/ggi.13682. Epub 2019 Apr 29.
- Kim R, Choi S, Kang N, Park K, Shin H, Lee H, Lee H, Jun JS, Jeon B, Byun K. Effects of high-intensity interval training and moderate-intensity continuous training on sarcopenia-related parameters in participants with Parkinson's disease: A 24-week randomized pilot trial substudy. Parkinsonism Relat Disord. 2023 Dec;117:105901. doi: 10.1016/j.parkreldis.2023.105901. Epub 2023 Oct 21.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 3103 / 05.08.2025
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。